Chromatography: TLC, Column & HPLC

Q1 — Sample Band 6 response (8 marks), annotated

Retention time is the time taken for a specific compound to travel from the injection point to the detector in an HPLC system under a defined set of conditions. When an unknown sample produces a peak at the same retention time as a certified standard under identical conditions, this supports the identification of that component as the same compound as the standard. [1 — defines retention time and states what matching means]

Comparing the two lots on three criteria from the data: number of peaks — Lot A produces 4 detectable peaks (peaks 1–4; peak 5 area = 0) while Lot B produces 5 detectable peaks (peaks 1–5), so Lot B contains an additional compound not present in Lot A. Retention times — for peaks 1–4, Lot A and Lot B produce peaks at identical retention times (4.2, 6.8, 9.1, 11.4 min), consistent with both lots containing the same four anthocyanins at those positions. Peak areas for peaks 1–4 — the areas are virtually identical across both lots (e.g. cyanidin-3-glucoside: 12 400 vs 12 350 mAU·s), indicating the concentrations of these four compounds are effectively the same. [3 — three explicit criteria with data references]

The key difference is that Lot B shows a peak at 14.2 min (peak 5, malvidin-3-glucoside, area 1 870 mAU·s) while Lot A shows no peak at that retention time (area = 0). This is analytically significant because malvidin-3-glucoside is the dominant anthocyanin in true Shiraz, and its complete absence in Lot A raises questions about Lot A’s variety identity, or alternatively a loss of malvidin through degradation or processing. [1 — identifies key difference with analytical significance]

Using peak area to reason quantitatively: peak area is proportional to concentration under fixed conditions. Lot B’s malvidin-3-glucoside peak (1 870 mAU·s) is a measurable fraction of the peak for cyanidin-3-glucoside (12 350 mAU·s), suggesting malvidin is present at roughly 15% of the level of the dominant pigment. This is a quantitatively detectable amount that would not be revealed on a TLC plate if the spot was too faint. [1 — peak area reasoning applied quantitatively]

Overall evidence-based judgement: the HPLC data are consistent with Lot B being authentic Shiraz (malvidin-3-glucoside is a characteristic Shiraz marker and is present), but the complete absence of malvidin in Lot A is inconsistent with authentic Shiraz identity unless there is an analytical or processing explanation. The data do not definitively establish fraud, but they do provide quantitative grounds to question the labelling of Lot A and justify further confirmatory testing such as mass spectrometry to absolutely confirm peak identities. [2 — evidence-based judgement with nuance and next-step reasoning]

Marking criteria:

• 1 mark — Defines retention time and explains that matching retention times under identical conditions supports (not proves) identification.
• 1 mark each (max 3) — Compares the two lots on three explicit criteria using specific data: number of peaks, retention times (1–4 match), and peak areas (1–4 match).
• 1 mark — Identifies peak 5 (malvidin-3-glucoside) as the key difference: absent in Lot A, present in Lot B, with a statement of why this is analytically significant.
• 1 mark — Uses peak area data quantitatively to reason about relative concentration, not just presence/absence.
• 1 mark — Reaches a qualified, evidence-based judgement about the labelling that does not overstate certainty and acknowledges limitations (retention time supports but does not prove identity without additional confirmation).
• 1 mark — Overall response uses precise HPLC terminology throughout (retention time, peak area, UV detection, identical conditions, mAU·s) and makes the analysis explicit rather than general.

Q2 — Sample Band 6 source critique (7 marks), annotated

The claim is partly correct but contains significant scientific flaws. [1 — overall evaluative judgement]

What is defensible: HPLC is widely regarded as a “gold standard” analytical method in pharmaceutical and food chemistry because it is fast, sensitive and quantitative. It is also correct that HPLC is quantitative while TLC is at best semi-quantitative. [1 — concedes valid element]

Flaw 1 — “same retention time = definitely same compound.” This is false. Retention time supports identification under a given set of conditions, but two different compounds can share the same retention time on a particular column with a particular mobile phase (co-elution). Definitive identification requires additional evidence such as mass spectrometry or UV spectral matching. The lesson states explicitly: “A matching time is strong evidence, but not absolute proof on its own.” [2 — identifies flaw and explains correct chemistry with lesson evidence]

Flaw 2 — “instrument reading is always correct.” Instrument readings are subject to systematic errors including detector calibration drift, injection volume variation, column degradation and interference from matrix components. All instrument results require validation and quality-control checks. [1 — identifies and corrects second flaw]

Flaw 3 — “TLC is obsolete and offers no useful information HPLC does not.” TLC has legitimate ongoing uses: it is fast, inexpensive, requires no expensive instrumentation, and is highly practical for rapid monitoring of reaction progress in synthetic chemistry, screening many samples simultaneously on one plate, and field-deployable forensic checks where HPLC equipment is unavailable. Its low cost makes it valuable as a preliminary filter before committing samples to HPLC analysis. [1 — correctly identifies a legitimate use of TLC]

Defensible reformulation: “HPLC is a highly sensitive, quantitative analytical technique widely used for drug purity testing. Matching retention times provide strong supporting evidence for identification, but not absolute proof without additional techniques such as mass spectrometry. TLC remains a valuable complementary tool for rapid, low-cost screening and reaction monitoring where its speed and accessibility outweigh its lower sensitivity and semi-quantitative nature.” [1 — defensible reformulation using lesson terminology]

Marking criteria:

• 1 mark — States an overall evaluative judgement (partly correct but substantially flawed).
• 1 mark — Correctly identifies the defensible elements (HPLC is sensitive; HPLC is quantitative while TLC is not).
• 2 marks — Identifies the “same retention time = definitely same compound” flaw and explains why: co-elution is possible; retention time is supporting evidence not absolute proof; additional confirmation methods are needed.
• 1 mark — Identifies and corrects the “instrument is always correct” flaw with reference to systematic errors, calibration or validation requirements.
• 1 mark — Correctly identifies at least one legitimate and specific use of TLC not replaced by HPLC (e.g. reaction progress monitoring, simultaneous multi-sample screening, low-cost field deployment).
• 1 mark — Provides a biologically/analytically defensible reformulation that accurately reflects lesson content and uses precise terminology.

Q3 — Sample Band 6 response (6 marks)

The claim is partly correct but analytically flawed at its core. [1 — judgement]

What is defensible: TLC is genuinely faster and simpler to set up than HPLC; it requires no expensive pumps, columns or detectors, and Rf values can provide supporting evidence for compound identity by comparison with certified standards on the same plate. [1 — concedes valid element]

What is flawed — sensitivity and detection of trace impurities: TLC has moderate sensitivity and cannot reliably detect impurities present at very low concentrations (e.g. <0.1% of the main component). Pharmaceutical release testing requires quantitative evidence that impurity levels are below regulatory safety limits. TLC does not provide this: it cannot accurately quantify impurity levels, particularly trace impurities, meaning it cannot satisfy the TGA’s requirement for precise purity data. [2 — identifies and explains the central analytical flaw]

What is flawed — “no analytical reason to use HPLC”: HPLC provides peak areas proportional to concentration, enabling precise quantification of both active ingredient and impurities. This quantitative data is not available from TLC. Regulatory guidelines (such as ICH Q3A) require quantitative impurity profiling for pharmaceutical products; TLC cannot meet this standard. [1 — identifies quantitative requirement flaw]

Defensible reformulation: “TLC is a valuable, fast and cost-effective technique for rapid screening and identity checking, but it cannot replace HPLC for pharmaceutical release testing because HPLC provides the quantitative sensitivity and precision needed to confirm that impurity levels are below regulatory safety thresholds. In practice, TLC and HPLC are complementary methods, not alternatives.” [1 — defensible reformulation]

Marking criteria:

• 1 mark — States overall evaluative judgement (partly correct but analytically flawed).
• 1 mark — Correctly identifies the defensible element (TLC is fast, simple and inexpensive; Rf can support identity).
• 2 marks — Explains the central flaw: TLC cannot quantify trace impurities; pharmaceutical testing requires quantitative purity data to meet regulatory standards (TGA, ICH). Both the “sensitivity” and “quantitative” limitations must be addressed.
• 1 mark — Identifies that the “no analytical reason to use HPLC” claim is wrong because HPLC’s quantitative peak area data is essential for regulatory compliance (which TLC cannot provide).
• 1 mark — Provides a defensible reformulation that frames TLC and HPLC as complementary and specifies the context in which each is appropriate, using lesson terminology.